Market Cap 1.07B
Revenue (ttm) 6.24M
Net Income (ttm) -84.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,361.70%
Debt to Equity Ratio 0.00
Volume 779,300
Avg Vol 775,828
Day's Range N/A - N/A
Shares Out 32.19M
Stochastic %K 11%
Beta 1.58
Analysts Strong Sell
Price Target $63.45

Company Profile

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company's lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinati...

Industry: Biotechnology
Sector: Healthcare
Phone: 929 999 4055
Address:
7 Times Square, 43rd Floor, New York, United States
OpenOutcrier
OpenOutcrier Oct. 16 at 12:44 PM
$DNTH (+0.9% pre) Dianthus Therapeutics licenses DNTH212 from Leads Biolabs https://ooc.bz/l/80760
0 · Reply
JarvisFlow
JarvisFlow Oct. 14 at 1:07 PM
Truist Securities has adjusted their stance on Dianthus Therapeutics ( $DNTH ), setting the rating to Buy with a target price of 56.
0 · Reply
Quantumup
Quantumup Oct. 14 at 10:43 AM
Truist🏁 $DNTH Buy/$56 $ARGX $AZN NVS $JNJ $IMVT CABA Truist said in its initiation report: Dianthus' differentiated approach to targeting the autoantibody mediated complement cascade (C1s inhibition), may offer similar efficacy as available complement (C5) inhibitors, but with a cleaner safety profile. The recent Ph 2 proof-of-concept (PoC) results with claseprubart in generalized myasthenia gravis (gMG) were overall supportive of this thesis. In our view, gMG data are also relatively de-risking for the ongoing Ph 3 chronic inflammatory demyelinating polyneuropathy (CIDP) trial, for which we see significant upside potential upon positive data in 2H26.
0 · Reply
Doozio
Doozio Oct. 1 at 4:17 PM
$DNTH no it won’t. Bahhht it was always 🐒🍌🧠⏰♾️ wen MLYS are becoming BILI’s.
0 · Reply
Ryder845
Ryder845 Sep. 26 at 4:08 AM
$DNTH big money on insider option trades.
0 · Reply
theflynews
theflynews Sep. 22 at 10:58 AM
Short Report: Dave & Busters bears boost exposure - $DNTH - https://thefly.com/permalinks/entry.php/DNTHid4201028?1758537978C38
0 · Reply
SuzannaMcclung593
SuzannaMcclung593 Sep. 21 at 8:50 AM
$DNTH Biotech with phase II data. High risk speculation. Trading near cash value. No pattern.
0 · Reply
topstockalerts
topstockalerts Sep. 19 at 7:55 PM
Several companies saw notable activist-investor moves last week (Sept. 11–17, 2025) via SEC 13D filings. Increases in holdings: Fairmount Funds Management boosted its stake in Dianthus Therapeutics to 4,052,052 shares by buying 600,000 shares at $33 each, now owning 9.9% of the company. Dianthus shares have risen ~67.6% this year. Decreases in holdings: Scorpio Tankers reduced its DHT Holdings stake to 6,157,480 shares, below the 5% reporting threshold; DHT shares are up ~34.3% YTD. TGP GP A sold 3,573,836 Life Time Group Holdings shares, keeping an 8.1% stake; LTH shares have gained ~24.2% YTD. American Industrial Partners sold 1.7M V2X shares, reducing its stake to 26.9% and losing a board seat; VVX shares are up ~20.2% YTD. Access Industries cut Opendoor Technologies holdings to 42,724,914 shares via a 10.87M share sale; OPEN shares have surged ~542.1% YTD. $DNTH $DHT $LTH $OPEN
0 · Reply
JarvisFlow
JarvisFlow Sep. 17 at 1:47 PM
Clear Street has updated their rating for Dianthus Therapeutics ( $DNTH ) to Buy with a price target of 100.
0 · Reply
Quantumup
Quantumup Sep. 16 at 8:39 PM
Clear Street initiated $DNTH Buy/$100. [ $AZN $JNJ REGN $ARGX $SNY] Clear Street said: Dianthus is a biotechnology company primarily developing claseprubart for the treatment of complement-driven autoimmune diseases. We believe claseprubart is a best-in-class complement inhibitor and is well positioned to improve on the standard of care in each of the three indications currently being tested in the clinic: generalized myasthenia gravis (gMG), chronic idiopathic demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN). We believe that strong Ph2 data in gMG earlier this month support the molecule's opportunity not only in gMG, but also in CIDP and MMN (both expect data updates in 2H26). Given the >$1-2B size of each of these opportunities, impressive clinical data, strong scientific rationale, and encouraging PK/PD data, we believe that there is room for shares to appreciate from the current ~$900M EV (pro forma post-raise) despite the stock's strong performance YTD.
0 · Reply
Latest News on DNTH
Magenta Therapeutics to Explore Strategic Alternatives

Feb 2, 2023, 4:05 PM EST - 2 years ago

Magenta Therapeutics to Explore Strategic Alternatives


OpenOutcrier
OpenOutcrier Oct. 16 at 12:44 PM
$DNTH (+0.9% pre) Dianthus Therapeutics licenses DNTH212 from Leads Biolabs https://ooc.bz/l/80760
0 · Reply
JarvisFlow
JarvisFlow Oct. 14 at 1:07 PM
Truist Securities has adjusted their stance on Dianthus Therapeutics ( $DNTH ), setting the rating to Buy with a target price of 56.
0 · Reply
Quantumup
Quantumup Oct. 14 at 10:43 AM
Truist🏁 $DNTH Buy/$56 $ARGX $AZN NVS $JNJ $IMVT CABA Truist said in its initiation report: Dianthus' differentiated approach to targeting the autoantibody mediated complement cascade (C1s inhibition), may offer similar efficacy as available complement (C5) inhibitors, but with a cleaner safety profile. The recent Ph 2 proof-of-concept (PoC) results with claseprubart in generalized myasthenia gravis (gMG) were overall supportive of this thesis. In our view, gMG data are also relatively de-risking for the ongoing Ph 3 chronic inflammatory demyelinating polyneuropathy (CIDP) trial, for which we see significant upside potential upon positive data in 2H26.
0 · Reply
Doozio
Doozio Oct. 1 at 4:17 PM
$DNTH no it won’t. Bahhht it was always 🐒🍌🧠⏰♾️ wen MLYS are becoming BILI’s.
0 · Reply
Ryder845
Ryder845 Sep. 26 at 4:08 AM
$DNTH big money on insider option trades.
0 · Reply
theflynews
theflynews Sep. 22 at 10:58 AM
Short Report: Dave & Busters bears boost exposure - $DNTH - https://thefly.com/permalinks/entry.php/DNTHid4201028?1758537978C38
0 · Reply
SuzannaMcclung593
SuzannaMcclung593 Sep. 21 at 8:50 AM
$DNTH Biotech with phase II data. High risk speculation. Trading near cash value. No pattern.
0 · Reply
topstockalerts
topstockalerts Sep. 19 at 7:55 PM
Several companies saw notable activist-investor moves last week (Sept. 11–17, 2025) via SEC 13D filings. Increases in holdings: Fairmount Funds Management boosted its stake in Dianthus Therapeutics to 4,052,052 shares by buying 600,000 shares at $33 each, now owning 9.9% of the company. Dianthus shares have risen ~67.6% this year. Decreases in holdings: Scorpio Tankers reduced its DHT Holdings stake to 6,157,480 shares, below the 5% reporting threshold; DHT shares are up ~34.3% YTD. TGP GP A sold 3,573,836 Life Time Group Holdings shares, keeping an 8.1% stake; LTH shares have gained ~24.2% YTD. American Industrial Partners sold 1.7M V2X shares, reducing its stake to 26.9% and losing a board seat; VVX shares are up ~20.2% YTD. Access Industries cut Opendoor Technologies holdings to 42,724,914 shares via a 10.87M share sale; OPEN shares have surged ~542.1% YTD. $DNTH $DHT $LTH $OPEN
0 · Reply
JarvisFlow
JarvisFlow Sep. 17 at 1:47 PM
Clear Street has updated their rating for Dianthus Therapeutics ( $DNTH ) to Buy with a price target of 100.
0 · Reply
Quantumup
Quantumup Sep. 16 at 8:39 PM
Clear Street initiated $DNTH Buy/$100. [ $AZN $JNJ REGN $ARGX $SNY] Clear Street said: Dianthus is a biotechnology company primarily developing claseprubart for the treatment of complement-driven autoimmune diseases. We believe claseprubart is a best-in-class complement inhibitor and is well positioned to improve on the standard of care in each of the three indications currently being tested in the clinic: generalized myasthenia gravis (gMG), chronic idiopathic demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN). We believe that strong Ph2 data in gMG earlier this month support the molecule's opportunity not only in gMG, but also in CIDP and MMN (both expect data updates in 2H26). Given the >$1-2B size of each of these opportunities, impressive clinical data, strong scientific rationale, and encouraging PK/PD data, we believe that there is room for shares to appreciate from the current ~$900M EV (pro forma post-raise) despite the stock's strong performance YTD.
0 · Reply
JarvisFlow
JarvisFlow Sep. 12 at 12:30 PM
Wedbush has adjusted their stance on Dianthus Therapeutics ( $DNTH ), setting the rating to Outperform with a target price of 42 → 44.
0 · Reply
SnipetheSpike
SnipetheSpike Sep. 11 at 6:05 PM
$DNTH Unitronix holding higher time frame supports beautifully risk defined entries everywhere reward skewed massively toward upside continuation
0 · Reply
RunnerSignals
RunnerSignals Sep. 10 at 8:36 PM
Green Machine Rolling! $LUMN $SWIN $SWBI $DNTH $CHGG all firing on all cylinders today! When the market gives you lemons, these tickers made lemonade
0 · Reply
kshonstocks
kshonstocks Sep. 10 at 7:10 PM
v good action off of offering $DNTH
0 · Reply
Quantumup
Quantumup Sep. 10 at 3:33 PM
Jefferies⬆️ $DNTH's PT to $66, reiterated Buy and said, we believe $DNTH is undervalued at~$580M EV following (+)ve de-risking gMG ph.Il data based on est $2B peak sales in gMG, CIDP, & MMN. Updates from maturing OLE can derisk pot'l monthly dosing. 2026 will be catalyst-rich: 1) $ARGX's DM ph.ll 1H26; 2) CIDP ph.Ill interim responder analysis 2H26; 3) MMN ph.Il top-line 2H26; 4) 2H26 pivotal readouts from $SNY (CIDP) & $ARGX (MMN). PT to $66 (vs prior $51).
0 · Reply
DonCorleone77
DonCorleone77 Sep. 10 at 10:09 AM
$DNTH Dianthus 6.49M share Secondary priced at $33.00
0 · Reply
AlertsAndNews
AlertsAndNews Sep. 10 at 2:37 AM
$DNTH | Dianthus Prices $251M Upsized Public Offering Dianthus Therapeutics priced 6.49M shares at $33 each and 1.11M pre-funded warrants at $32.999, raising ~$251M in gross proceeds. The biotech granted underwriters a 30-day option to buy up to 1.14M additional shares. The deal is expected to close Sept. 11, 2025.
0 · Reply
RunnerSignals
RunnerSignals Sep. 9 at 8:50 PM
$ATXS $DNTH $SION $SEZL $SDGR analysts see stars, but will these rockets launch? Strap in, it's gonna be a wild ride! https://stocksrunner.com/news/2025-09-09-unlocking-stocks-with-analyst-upgrades-and-short-term-upside-potential
0 · Reply
RunnerSignals
RunnerSignals Sep. 9 at 8:42 PM
Analyst upgrades are flying today! $ALAB $CPNG $DNTH $NVO $AEM all getting love and upgrades https://stocksrunner.com/news/2025-09-09-stock-upgrades-today-signal-fresh-trading-opportunities
0 · Reply
JustAnotherGuy007
JustAnotherGuy007 Sep. 9 at 7:18 PM
$BTAI BioXcel Therapeutics Why It Matters: Low float, Phase III data expected this month for its AI-developed agitation treatment; high volatility and clear breakout setup. ([turn0search9]) Catalyst: Top-line data likely soon—ideal for time-sensitive long calls. $DNTH Dianthus Therapeutics Why It Matters: Shares surged recently on positive Phase II results for autoimmune drug claseprubart. Expectations are high as the company heads into Phase III. ([turn0news20]) Catalyst: Potential Phase III trial announcements—amazingly event-rich, with upside and follow-on visibility. $ABBV (AbbVie) Why It Matters: Late-stage trial results for Rinvoq (vitiligo); potential near-term catalyst. ([turn0news21]) Catalyst: Readouts are expected later in 2025—makes it a candidate for September–October plays.
0 · Reply
anachartanalyst
anachartanalyst Sep. 9 at 5:02 PM
$DNTH https://anachart.com/wp-content/uploads/ana_temp/1757437312_soc-img.jpg
0 · Reply
BrianRix
BrianRix Sep. 9 at 3:15 PM
$DNTH 40s next week
0 · Reply